



Rearrangement of carbiminium carbonylmetalates by mutual exchange of alkoxy- and amino functionalities ($M = W, Cr$)[☆] Crystal structure analyses

Rudolf Aumann ^{*}, Klaus Roths, Roland Fröhlich

Organisch-Chemisches Institut, Universität Münster, Corrensstrasse 40, D-48149 Münster, Germany

Received 13 July 2000; accepted 23 August 2000

Abstract

Reaction of (1-alkynyl)carbene complexes $(CO)_5M=C(OEt)C\equiv CPh$ (**1a,b**) ($M = Cr, W$) with enamines $R'(R_2N)C=CHR''$ (**4a–d**) ($R_2N = \text{morpholine}$) yielded carbiminium carbonylmetalates $[(OC)_5M-C(OEt)=C[C(=N^+R_2)R']C(Ph)=CHR'']$ (**5**) by metathesis of the $(N)C=C$ at the $C\equiv C$ bond. Compounds **5** are stable in solid state, but in solution they undergo a mutual exchange of the ethoxy- and the amino functionality to give isomers $[(OC)_5M-C(=N^+R_2)]C[=C(OEt)R']C(Ph)=CHR''$ (**6**). © 2001 Elsevier Science B.V. All rights reserved.

Keywords: Carbene complexes; Metalla hexatrienes; Carbiminium carbonylmetalates; Chromium and tungsten complexes; Enamines

1. Introduction

(1-Alkynyl)carbene complexes, e.g. $(CO)_5M=C(OEt)C\equiv CPh$ (**1a,b**) ($M = Cr, W$) are potentially useful reagents for the synthesis of organic compounds [1]. It was shown only recently that secondary enaminones, e.g. compounds **2** [2a,b] as well as tertiary cyclic enamines $\sim CH=C(NR_2) \sim$ [2c,d,e] undergo a 4-addition to the $C\equiv C$ bond of (1-alkynyl)carbene complexes **1a,b** under exceedingly mild conditions to afford conjugated 6-amino-1-metalla-1,3,5-hexatrienes $(OC)_5M=CC=CC=C(N)$, e.g. compounds **3** (Scheme 1), which could be further transformed into π - and α -cyclisation products [3]. Whilst pursuing these studies, a second reaction mode significantly different from the forementioned one was found, which yields ‘cross conjugated’ metalla hexatrienes $(OC)_5M=CC[=C(NR_2)]C=C$, e.g. compounds (*1E*)-**5** (Scheme 1) by dichotomy of the $(N)C=C$ bond at the $C\equiv C$ bond instead of conjugated metalla hexatrienes, e.g. compounds **3** by a Michael-type addition [4,5]. Although there is ample precedence for reactions of

enamines with alkynes, e.g. propargylic esters, in which cyclobutene derivatives are generated in the first reaction step and subsequently undergo ring opening to butadiene derivatives [6,7], reactions of enamines with (1-alkynyl)carbene complexes **1** leading to formation of stable ‘cross-conjugated’ metallatrienes of type (*1E*)-**5** instead of conjugated 1-metalla-1,3,5-trienes (**3**) had not been reported [8].

2. Results and discussion


It has been found that carbiminium carbonylmetalates (*1E*)-**5** containing a pyrrolidine unit ($R_2N=C_4H_8N$) would undergo a (*1E/1Z*) isomerisation, which appears to be reversible and seems to be governed by the dipole moment of the corresponding isomers (Scheme 2) [4b]. We now wish to report that this type of (*1E/1Z*) rearrangement strongly depends on the type of amine substituent. Whilst it was found to be the major reaction of pyrrolidine derivatives **5** it became a minor side reaction in case of compounds (*1E*)-**5** containing a (less basic) morpholine unit ($R_2N=C_4H_8NO$) instead of a (more basic) pyrrolidine moiety, since it was outrun by a mutual exchange of the ethoxy- and the morpholine group to give compounds **6**.

[☆] Part 108 of the series: Organic Syntheses via Transition Metal Complexes. For preceding paper see Ref. [11].

* Corresponding author. Fax: +49-251-8336502.

E-mail address: aumannr@uni-muenster.de (R. Aumann).


It is suggested that the transformation of carbiminium carbonylmetalates (*1E*)-**5** into (thermodynamically more stable) isomers **6** would involve an equilibrium between zwitterionic intermediates **A** and **C** via formation of vinylidene complexes **B** (Scheme 3).



(<i>1E</i>)- 5	M	NR ₂	R'	R''	5[%]	$\delta(M=C)$	$\delta(C=N^+)$	$\delta(4-H)$	Lit.
a	W	morpholino	Me	CO ₂ Me	93	254.4	180.5	5.90	[b]
b	Cr	morpholino	Me	CO ₂ Me	91	[a]	174.7	5.74	[b]
c	W	morpholino	Me	CO ₂ CH ₂ Ph	87	[a]	180.2	5.98	[b]
d	W	morpholino	Me	CO ₂ iBu	89	252.2	180.1	5.97	[b]
e	W	morpholino	Me	Ph	90	[a]	[a]	6.80	[b]
f	W	morpholino	H	Me	93	277.8	167.1	5.51	5
g	W	morpholino	H	iPr	95	278.1	166.8	5.16	5

[a] Not observed due to dynamic broadening at 242 K. [b] This paper.


Scheme 1. Different reaction modes of secondary enaminones and tertiary enamines, respectively, with (1-alkynyl)carbene complexes **1** (M = W, Cr); chemical yields and characteristic NMR shifts of carbiminium carbonylmetalates (*1E*)-**5** (in CDCl₃ at 242 K).



(<i>1E</i>)- 5,6	M	NR ₂	R'	R'	(<i>1E</i>)- 5/6 [a]	6 : $\delta(M=C)$	Lit.
a	W	morpholino	Me	CO ₂ Me	1/6	254.7	[b]
b	Cr	morpholino	Me	CO ₂ Me	0/1	273.7	[b]
c	W	morpholino	Me	CO ₂ CH ₂ Ph	1/2	253.8	[b]
d	W	morpholino	Me	CO ₂ iBu	1/6	254.2	[b]
e	W	morpholino	Me	Ph	0/1	254.7	[b]
f	W	morpholino	H	Me	0/1	252.9	5
g	W	morpholino	H	iPr	0/1	255.0	5

[a] Product ratio according to NMR spectra of the mixture. [b] This paper.

Scheme 2. Thermal (1*E*/1*Z*) isomerisation of 4-iminium carbonylmetalates **5** and formation of 2-iminium carbonylmetalates **6** by a 1,3 shift of the imino unit.



Scheme 3. Reaction path suggested for a 1,3 shift of the iminium functionality of carbiminium carbonylmetalates (*1E*)-**5**.

The transformation of the 4- into 2-carbiminium complexes, (*1E*)-**5** and **6**, respectively, was followed by ¹H-NMR spectra. Characteristic spectral changes include a significant high-field shift of the signals OCH₂ [e.g. (*1E*)-**5a**: δ 4.21; **6a**: AB-system δ 3.73 and 3.27], a strong diastereotopic splitting of the methylene protons [e.g. NCH₂ and OCH₂ of **6a**: δ 5.70–3.30] as well as of the corresponding carbon signals [e.g. (*1E*)-**5a**: δ (OCH₂CH₃) 73.9; (OCH₂ morpholine) 66.1; (NCH₂ morpholine) 51.8. **6a**: 67.6, 67.0, 64.2, 63.0 and 53.3]. The chemical shifts of the carbene carbon atoms of compounds (*1E*)-**5a–d** and **6a–d** are in a range typically observed for carbiminium carbonylmetalates [e.g. (*1E*)-**5a**: δ (W–C) 254.4, **6a**: 254.7], at somewhat higher field than observed for 4-amino-tungsta-1,3-butadienes [e.g. (OC)₅W=C(OEt)CH=C(NMe₂)Ph δ 269.7]. Furthermore, a relative high field shift of 4-H is observed for compounds **6** compared to iminium complex (*1E*)-**5** [e.g. (*1E*)-**5a**: δ 5.90; **6a**: 5.41]. The transformation of compounds (*1E*)-**5a** into **6a** involves a configurational change of C3=C4 leading to a NOE enhancement of OCH₂ (morpholine) as well as of ortho-phenyl on irradiation of 4-H.

Structural details of compounds (*1Z*)-**5a** were provided by a crystal structure analysis (Fig. 1). The compound shows a carbiminium carbonylmetalate unit, which is characterized by a pattern of alternating bond distances of the W–C=C–C=N⁺ backbone [W–C2 2.292(5) Å, C2=C3 1.418(7), C3=C6 1.463(7), C6=N1 1.312(7)], a slightly distorted *cisoid* arrangement of the W–C2=C3–C6 moiety [dihedral angle –34.4(7)^o] and a stronger distortion of the *transoid* C2=C3–C6=N1 unit [dihedral angle 143.3(6)^o]. Especially the latter feature excludes the presence of an en amino unit, since this would imply a planar C3=C6 double bond. The

$C_2=C_3-C_4=C_5$ portion of the molecule adopts a *transoid* conformation [dihedral angle $140.1(6)^\circ$], and shows an essential planar *cis* arrangement of the $C_3-C_4-C_5-C_51 - 9.2(10)$ group as well as a slightly distorted ester functionality [dihedral angle $C_4-C_5-C_51-O_51 - 20.7(10)$].

Carbiminium carbonylmetalates **6** were characterized by NMR spectra and a crystal structure analysis of compound **6a** (Fig. 2). The latter compound exhibits a long distance between C_2-C_3 1.514(15) and a short distance $C_2=N_2$ 1.318(13) as well as a strong distortion of $W-C_2-C_3=C_6$ $96.3(9)^\circ$ [$N_2-C_2-C_3=C_6 - 80.5(12)$]. The $C_6=C_3-C_4-C_5-C_51$ diene portion of the molecule shows alternating bond distances [$C_3=C_6$ 1.331(14), C_3-C_4 1.464(14), C_4-C_5 1.38(2) and C_5-C_51 1.44(2)] and adopts a *transoid* conformation, $C_6=C_3-C_4=C_5$ $148.7(11)^\circ$, $C_3-C_4-C_5-C_51$ 175.6(11) and $C_4-C_5-C_51-O_51 - 21.3(23)$.

3. Experimental

All operations were performed under argon. Dried solvents were used in all experiments. Melting points are not corrected. Instrumentation: 1H - and ^{13}C -NMR spectra were obtained with Bruker ARX 300, Bruker




Fig. 1. Molecular structure of carbiminium carbonyltungstate (1Z)-**5a**. Selected bond distances (\AA) and angles ($^\circ$): W–C2 2.292(5), C2–O1 1.355(6), C2–C3 1.418(7), O1–C13 1.441(7), C13–C14 1.490(9), C3–C6 1.463(7), C3–C4 1.499(8), C4–C5 1.328(8), C5–C51 1.466(8), C51–O51 1.212(7), C51–O52 1.324(7), O52–C53 1.436(7), C6–N1 1.312(7), C6–C7 1.491(8), N1–C8 1.483(7), N1–C12 1.482(8), C8–C9 1.472(11), C9–O10 1.413(12), O10–C11 1.420(9), C11–C12 1.494(9); O1–C2–C3 106.1(5), O1–C2–W 124.5(4), C3–C2–W 127.7(4), C2–O1–C13 123.8(4), O1–C13–C14 108.7(5), C2–C3–C4 120.4(5), C2–C3–C6 120.8(5), C4–C3–C6 118.8(5), C5–C4–C41 117.9(5), C3–C4–C5 123.8(5), C3–C4–C41 118.1(5), C4–C41–C42 121.0(6), C4–C41–C46 121.4(5), C4–C5–C51 128.9(6), C5–C51–O51 126.4(6), C5–C51–O52 111.6(6), O51–C51–O52 122.0(6), C51–O52–C53 117.5(5), C3–C6–N1 121.0(5), C3–C6–C7 120.2(5), N1–C6–C7 118.5(5), C6–N1–C8 124.6(6), C6–N1–C12 125.3(5), C8–N1–C12 110.1(5), N1–C8–C9 111.1(6), C8–C9–O10 114.2(9), C9–O10–C11 109.1(7), O10–C11–C12 110.4(7), C11–C12–N1 111.1(6).





Fig. 2. Molecular structure of carbiminium carbonyltungstate **6a**. Selected bond lengths (\AA) and angles ($^\circ$): W–C2 2.247(9), C2–N2 1.318(13), C2–C3 1.514(15), N2–C10 1.479(14), N2–C14 1.480(14), C11–C10 1.49(2), C3–C6 1.331(14), C3–C4 1.464(14), C6–O1 1.379(12), C6–C7 1.51(2), O1–C8 1.413(14), C8–C9 1.46(2), C4–C5 1.38(2), C4–C41 1.48(2), C5–C51 1.44(2), C51–O51 1.256(14), C51–O52 1.288(14), O52–C53 1.41(2); N2–C2–C3 114.4(9), N2–C2–W 129.8(8), C3–C2–W 115.7(6), C2–N2–C10 124.6(9), C2–N2–C14 125.2(10), C10–N2–C14 110.3(9), N2–C14–C13 109.9(11), N2–C10–C11 109.1(10), C6–C3–C4 123.2(10), C6–C3–C2 119.4(9), C4–C3–C2 117.4(9), C3–C6–O1 118.8(9), C3–C6–C7 124.2(10), O1–C6–C7 116.7(10), C6–O1–C8 118.8(9), C5–C4–C3 115.8(10), C5–C4–C41 123.8(10), C3–C4–C41 120.5(9), C42–C41–C4 120.8(11), C46–C41–C4 120.3(9), C4–C5–C51 128.3(11), O51–C51–C5 125.3(12), O52–C51–C5 113.0(11), C51–O52–C53 122.8(12).

AM 360 und Varian U 600 spectrometers. Chemical shifts refer to $\delta_{\text{TMS}} = 0.00$ ppm. Other analyses: IR Digilab FTS 45; MS Finnigan MAT 312; elemental analysis with Perkin–Elmer 240 elemental analyzer; TLC with Merck DC-Alufolien Kieselgel 60 F_{254} . R_f values refer to TLC tests. Column chromatographic purifications were achieved with Merck Kieselgel 100. Pentacarbonyl[1-ethoxy-3-phenyl-2-propin-1-ylidene]-tungsten (**1a**) and -chromium (**1b**) were prepared according to the procedure given in Ref. [1].


3.1. Pentacarbonyl[1-ethoxy-5-methoxy-2-(1-morpholinium-1-ethylidene)-5-oxo-3-phenyl-penta-1,3-dien-1-yl]tungstate [(1E)- and (1Z)-**5a**] and pentacarbonyl[2-(1-ethoxy-ethylidene)-5-methoxy-1-morpholinium-5-oxo-3-phenyl-3-penten-1-yl]tungstate (**6a**)

A mixture of pentacarbonyl(1-ethoxy-3-phenyl-2-propin-1-ylidene)tungsten (**1a**, 482 mg, 1.00 mmol) and

3-morpholino-but-2-enoic acid methylester (**4a**, 185 mg, 1.00 mmol) in 20 ml of *n*-pentane is vigorously stirred in a centrifuge tube for 1 h at 20°C to give a yellow precipitate of compound (*1E*)-**5a**, which is isolated by centrifugation and washed twice with 5 ml of *n*-pentane each [606 mg, 98%, m.p. (dec.) 74°C, R_f = 0.1 in diethyl ether–pentane (1:1)]. (*1E*)-**5a** in CDCl₃ solution undergoes an isomerisation to a 1:6 mixture of compounds (*1Z*)-**5a** and **6a**, which is completed within 24 h at 20°C.




¹H-NMR (CDCl₃): δ 7.27 (5H, s, C₆H₅), 5.90 (1H, s, 4-H), 4.21 (3H, q, ³J = 7 Hz, OCH₂CH₃), 3.72 (4H, m, 2OCH₂, morpholine), 3.57 (3H, s, OCH₃), 3.53 (4H, m, 2NCH₂, morpholine), 2.31 (3H, s, N=CCH₃), 1.15 (3H, t, OCH₂CH₃). ¹³C-NMR (CDCl₃, 242 K): δ 254.4 (W-C), 202.8 and 199.4 [1: 4, *trans*- and *cis*-CO W(CO₅)], 180.5 (C_q, C=N⁺), 166.6 (C_q, COOCH₃), 156.5 (C_q, C3), 138.8 and 134.8 (C_q each, C2 and *iC* Ph), 128.7–127.5 (5CH Ph), 118.7 (CH, C4), 73.9 (OCH₂CH₃), 66.1 (broad, 2 diastereotopic OCH₂ of morpholine), 51.8 (broad, 2NCH₂ morpholine), 51.1 (OCH₃), 26.7 (OCH₂CH₃), 14.9 (NCCH₃). IR (diffuse reflection), cm^{−1}: 2051.0 (10), 1921.5 (100) and 1897.4 (80) [ν (C≡O)], 1712.6 (20) [ν (C=O)].



¹H-NMR (CDCl₃): δ 7.52 (2H, m, *o*-H Ph), 7.30 (3H, m, *m*- and *p*-H Ph), 6.27 (1H, s, 4-H), 4.39 (2H, q, OCH₂CH₃), 3.84 (4H, m, 2OCH₂ morpholine), 3.79 (3H, s, OCH₃), 3.60 (4H, m, 2NCH₂ morpholine), 2.46 (3H, s, N=CCH₃), 1.18 (3H, t, OCH₂CH₃). ¹³C-NMR (CDCl₃) δ (W-C) [9], 203.4 and 200.1 [1:4, *trans*- and *cis*-CO, W(CO₅)], δ [9] (C_q, C=N⁺), 166.8 (C_q, COOCH₃) 157.4 (C_q, C3), 143.7 (C_q, C2), δ [9] (C_q, *iC* Ph); 129.7, 129.0 and 128.6 (CH each, Ph), 117.8 (CH, C4), 75.1 (OCH₂CH₃), 66.6 (broad, 2OCH₂ morpholine), 52.8 (broad, 2NCH₂ morpholine), 51.5 (OCH₃) 25.8 (OCH₂CH₃), 15.6 (NCCH₃). IR (diffuse reflection, cm^{−1}: 2053.1 (20) and 1897.0

(100) [ν (C≡O)], 1710.2 (20) [ν (C=O)]. X-ray crystal structure analysis of compound (*1Z*)-**5a**: formula C₂₅H₂₅NO₉W, M = 667.31, red crystal 0.25 × 0.20 × 0.15 mm, a = 19.737(1), b = 10.662(1), c = 25.249(1) Å, β = 107.56(1)°, V = 5065.7(6) Å³, ρ_{calc} = 1.750 g cm^{−3}, μ = 46.14 cm^{−1}, empirical absorption correction via ψ -scan data (0.957 ≤ C ≤ 0.999), Z = 8, monoclinic, space group *C*2/c (no. 15), λ = 0.71073 Å, T = 293 K, ω -2θ scans, 5279 reflections collected (− h , − k , ± l), $[(\sin \theta)/\lambda]$ = 0.62 Å^{−1}, 5129 independent (R_{int} = 0.023) and 3548 observed reflections [I ≥ 2σ(I)], 328 refined parameters, R = 0.033, wR^2 = 0.070, max. residual electron density 1.49 (−1.14) e Å^{−3} close to tungsten, hydrogen calculated and refined as riding atoms [10].



¹H-NMR (CDCl₃): δ 7.27 (5H, m, Ph), 5.41 (1H, s, 4-H), 5.70–3.30 (8H, m, 2OCH₂ and 2NCH₂ morpholine), 3.73 and 3.27 (1H each, diastereotopic OCH₂CH₃), 3.50 (3H, s, OCH₃), 1.79 [3H, s, =C(OEt)CH₃], 0.63 (3H, t, OCH₂CH₃). ¹³C-NMR (CDCl₃) δ 254.7 (W-C=N⁺), 202.8 and 198.6 [1:4, *trans*- and *cis*-CO W(CO₅)], 166.2 (C_q, COOCH₃); 148.6, 146.0 and 140.1 (C_q each; C1', C2 and C3), 137.5 (C_q, *iC* Ph), 127.9 and 127.7 (CH each, Ph), 120.1 (CH, C4); 67.6, 64.2 and 63.0 (OCH₂ each, Et and morpholine), 53.3 (broad, 2NCH₂ morpholine), 51.5 (OCH₃), 17.1 (CH₃, C2'), 15.6 (OCH₂CH₃). IR (diffuse reflection), cm^{−1}: 2058.9 (30), 1908.8 (100) [ν (C≡O)], 1724.3 (20) [ν (C=O)]. MS (70 eV, *m/e* (%)) ¹⁸⁴W: 667 (10) [M⁺], 315 (35) [ligand], 314 (100). Anal. Found: C, 44.78; H, 4.02; N, 2.10. Calc. for C₂₅H₂₅NO₉W (667.3): C, 45.00; H, 3.78; N, 2.10%. X-ray crystal structure analysis of compound **6a**: formula C₂₅H₂₅NO₉W, M = 667.31, yellow–red crystal 0.40 × 0.20 × 0.10 mm, a = 8.312(2), b = 11.362(3), c = 15.432(5) Å, α = 108.07(3), β = 100.55(2), γ = 93.37(2)°, V = 1351.7(7) Å³, ρ_{calc} = 1.640 g cm^{−3}, μ = 83.56 cm^{−1}, empirical absorption correction via ψ -scan data (0.583 ≤ C ≤ 0.999), Z = 2, triclinic, space group *P*−*1* (no. 2), λ = 1.54178 Å, T = 293 K, ω -2θ scans, 5894 reflections collected (+ h , ± k , ± l), $[(\sin \theta)/\lambda]$ = 0.62 Å^{−1}, 5497 independent (R_{int} = 0.088) and 4419 observed reflections [I ≥ 2σ(I)], 329 refined parameters, R = 0.067, wR^2 = 0.174, max. residual

electron density 2.23 (-2.14) e Å $^{-3}$ close to tungsten, hydrogen calculated and refined as riding atoms [10].

3.2. Pentacarbonyl[1-ethoxy-5-methoxy-2-(1-morpholinium-1-ethylidene)-5-oxo-3-phenyl-penta-1,3-dien-1-yl]chromate [(1E)- and (1Z)-**5b**] and pentacarbonyl[2-(1-ethoxy-ethylidene)-5-methoxy-1-morpholinium-5-oxo-3-phenyl-3-penten-1-yl]chromate (**6b**)

A mixture of pentacarbonyl(1-ethoxy-3-phenyl-2-propin-1-ylidene)chromium (**1b**, 351 mg, 1.00 mmol) and 3-morpholino-but-2-enoic acid methylester (**4a**, 185 mg, 1.00 mmol) in 20 ml of *n*-pentane is reacted as described above to give compound (1E)-**5b** [487 mg, 78%, m.p. (dec.) 78°C, R_f = 0.1 in diethyl ether-pentane (1:1)]. (1E)-**5b** in CDCl₃ solution undergoes an isomerisation within 24 h at 20°C to give compound **6b** as the only isolated product.

3.2.1. (1E)-**5b**

¹H-NMR (CDCl₃): δ 7.29 (5H, s, Ph), 5.74 (1H, s, 4-H), 4.35 (2H, diastereotopic OCH₂CH₃), 3.61 (4H, m, 2OCH₂, morpholine), 3.57 (3H, s, OCH₃), 3.31 (4H, m, 2NCH₂, morpholine), 2.20 (3H, s, NCCH₃), 1.31 (3H, t, OCH₂CH₃). ¹³C-NMR (CDCl₃ 242 K): δ [9] (Cr=C), 224.0 and 218.6 [1: 4, *trans*- and *cis*-CO, Cr(CO₅]₂, 174.7 (C_q, C=N⁺), 166.7 (C_q, COOCH₃), 155.3 (C_q, C3), 138.3 (C_q, C2), 134.8 (C_q, iC Ph); 128.8, 127.6 and 127.3 (CH each, Ph), 118.4 (CH, C4), 72.6 (OCH₂CH₃), 66.4 (broad, 2OCH₂, morpholine), 51.6 (broad, 2NCH₂, morpholine), 51.3 (OCH₃), 25.9 (OCH₂CH₃), 15.4 (NCCH₃). IR (diffuse reflection, cm $^{-1}$): 2049.1 (30), 1925.9 (100), 1898.6 (90) [ν (C≡O)], 1720.7 (20) [ν (C=O)].

3.2.2. Compound **6b**

¹H-NMR (CDCl₃): δ 7.27 (5H, m, Ph), 5.31 (1H, s, 4-H), 4.70–3.10 (8H, m, OCH₂ and NCH₂, morpholine), 3.65 and 3.21 (1H, diastereotopic OCH₂CH₃), 3.48 (3H, s, OCH₃), 1.73 [3H, s, =C(OEt)CH₃], 0.61 (3H, t, OCH₂CH₃). ¹³C-NMR (CDCl₃): δ 273.7 (Cr=C), 222.5 and 217.2 [1:4, *trans*- and *cis*-CO, Cr(CO₅]₂, 165.6 (C_q, COOCH₃); 148.1, 146.0 and 139.7 (C_q each; C1', C2 and C3), 131.1 (C_q, iC Ph), 127.5–127.2 (5CH, Ph), 119.3 (CH, C4); 67.2, 63.6 and 60.3 (OCH₂ each, OCH₂CH₃ and morpholine), 54.0 (2NCH₂ morpholine), 51.0 (OCH₃), 16.5 [=C(OEt)CH₃], 14.1 (OCH₂CH₃). IR (diffuse reflection), cm $^{-1}$: 2050.2 (30), 1972.7 (90), 1905.2 (100) [ν (C≡O)], 1724.4 (20) [ν (C=O)]. MS (70 eV), *m/e* (%), ¹⁸⁴W: 535 (4) [M⁺], 395 (20) [M⁺ – 5CO], 211 (20) [ligand], 141 (95), 52 (100). Anal. Found: C, 55.94; H, 4.87; N, 2.82. Calc. for C₂₅H₂₅NO₉Cr (535.5): C, 56.08; H, 4.71; N, 2.62%.

3.3. Pentacarbonyl[1-ethoxy-5-benzoxy-2-(1-morpholinium-1-ethylidene)-5-oxo-3-phenyl-penta-1,3-dien-1-yl]tungstate [(1E)- and (1Z)-**5c**] and pentacarbonyl[2-(1-ethoxy-ethylidene)-5-benzoxy-1-morpholinium-5-oxo-3-phenyl-3-penten-1-yl]tungstate (**6c**)

A mixture of pentacarbonyl(1-ethoxy-3-phenyl-2-propin-1-ylidene)tungsten (**1a**, 482 mg, 1.00 mmol) and 3-morpholino-but-2-enoic acid benzylester (**4b**, 227 mg, 1.00 mmol) in 20 ml of *n*-pentane is reacted as described above to give compound (1E)-**5c** [660 mg, 87%, m.p. (dec.) 80°C, R_f = 0.1 in diethyl ether-pentane (1:1)]. (1E)-**5c** in CDCl₃ solution undergoes an isomerisation within 24 h at 20°C to give compound (1Z)-**5c** and **6c** in a molar ratio 1:2.

3.3.1. (1E)-**5c**

¹H-NMR (C₆D₆, 360 MHz, 242 K): δ 7.40–7.00 (10H, m, Ph and CH₂Ph), 5.98 (1H, s, 4-H), 4.96 (2H, s, OCH₂Ph), 4.15 (2H, m, diastereotopic OCH₂CH₃), 3.62 (4H, broad, 2OCH₂ morpholine), 3.39 (4H, broad, 2NCH₂ morpholine), 2.19 (3H, s, N=CCH₃), 1.12 (3H, OCH₂CH₃). ¹³C-NMR (C₆D₆, 360 MHz, 242 K): δ [9] (W-C), 202.9 and 199.5 [1: 4, *trans*- and *cis*-CO, W(CO₅]₂, 180.2 (C_q, C=N⁺), 166.2 (C_q, COOCH₂Ph), 157.1 (C_q, C3), 139.1 (C_q, C2), 135.5 and 135.3 (C_q each, iC, Ph), 129–127 (5CH, Ph), 118.9 (CH, C4), 74.4 (OCH₂CH₃), 66.2 (2OCH₂ morpholine), 65.7 (OCH₂Ph), 51.9 (2NCH₂ morpholine), 27.1 (OCH₂CH₃), 15.1 (NCCH₃). IR (diffuse reflection), cm $^{-1}$: 2051.6 (20), 1919.5 (90) and 1876.2 (100) [ν (C≡O)], 1712.6 (20) [ν (C=O)].

3.3.2. (1Z)-**5c**

¹H-NMR (CDCl₃): δ 7.46 (2H, m, o-H Ph), 7.30 and 7.00 (6:2H, m, Ph and CH₂Ph), 6.24 (1H, s, 4-H), 5.04 (2H, diastereotopic CH₂Ph), 4.19 (2H, diastereotopic, OCH₂CH₃), 3.64 (4H, m, 2OCH₂ morpholine), 3.42 (4H, m, 2NCH₂ morpholine), 2.27 (3H, s, NCCH₃), 1.09 (3H, t, OCH₂CH₃). ¹³C-NMR (CDCl₃): δ [9] (W-C), 203.2 and 199.7 [1: 4, *trans*- and *cis*-CO, W(CO₅]₂, 165.7 (C_q, C=N⁺), 165.7 (C_q, COOCH₂Ph), 157.6 (C_q, C3), 142.2 (C_q, C2), [9] (C_q, iC 3-Ph), 136.4 (C_q, iC CH₂Ph), 129–127 (10CH, Ph and CH₂Ph), 117.3 (CH, C4), 73.9 (OCH₂CH₃), 65.9 (OCH₂Ph), 61.9 (2OCH₂, morpholine), 52.0 (2NCH₂, morpholine), 24.8 (NCCH₃), 15.1 (OCH₂CH₃).

3.3.3. Compound **6c**

¹H-NMR (CDCl₃): δ 7.29–7.15 (10H, m, Ph and CH₂Ph), 5.39 (1H, s, 4-H), 5.14 (2H, diastereotopic CH₂Ph), 4.60–3.10 (10H, m, 2OCH₂ and 2NCH₂ morpholine each, and OCH₂CH₃), 1.70 [3H, s,

$=\text{C}(\text{OEt})\text{CH}_3]$, 0.56 (3H, t, OCH_2CH_3). ^{13}C -NMR (CDCl_3): δ 253.8 (W-C), 212.3 and 198.7 [1:4, *trans*- and *cis*-CO, $\text{W}(\text{CO}_5)$, 165.3 (C_q , COOCH_2Ph); 147.8, 146.2 and 139.6 (C_q each; C1', C2 and C3), 135.7 and 131.9 (C_q each, *iC Ph*), 129–127 (CH, Ph and CH_2Ph), 119.9 (CH, C4); 67.2, 66.6, 66.1, 63.8 and 62.6 (OCH_2 each; morpholine, $\text{OCH}_2\text{C}_6\text{H}_5$ and OCH_2CH_3), 52.9 (2NCH₂, morpholine), 16.7 [$=\text{C}(\text{OEt})\text{CH}_3$], 14.0 (OCH_2CH_3). IR (diffuse reflection), cm^{-1} : 2058.3 (20), 1927.0 (90), 1902.1 (100) [$\nu(\text{C}\equiv\text{O})$, 1721.3 (20) [$\nu(\text{C=O})$. MS (70 eV, *m/e* (%), ^{184}W : 419 (50) [$\text{M}^+ - \text{W}(\text{CO}_5)$], 339 (100), 91 (100) [CH_2Ph^+]. Anal. Found: C, 44.73; H, 4.16; N, 1.61. Calc. for ($\text{C}_{31}\text{H}_{29}\text{NO}_9\text{W} \times \text{CHCl}_3$) (862.8): C, 44.55; H, 3.50; N, 1.63%.

3.4. Pentacarbonyl[1-ethoxy-5-(*t*-butoxy)-2-(1-morpholinium-1-ethylidene)-5-oxo-3-phenyl-penta-1,3-dien-1-yl]tungstate [(1*E*)- and (1*Z*)-**5d**] and pentacarbonyl[2-(1-ethoxy-ethylidene)-5-(*t*-butoxy)-1-morpholinium-5-oxo-3-phenyl-3-penten-1-yl]tungstate (**6d**)

A mixture of pentacarbonyl(1-ethoxy-3-phenyl-2-propin-1-ylidene)tungsten (**1a**, 482 mg, 1.00 mmol) and 3-morpholino-but-2-enoic acid *t*-butylester (**4c**, 203 mg, 1.00 mmol) in 20 ml of *n*-pentane is reacted as described above to give compound (1*E*)-**5d** [631 mg, 89%, m.p. (dec.) 99°C, $R_f = 0.1$ in diethyl ether–pentane (1:1)]. (1*E*)-**5d** in CDCl_3 solution undergoes an isomerisation within 24 h at 20°C to give compound (1*Z*)-**5c** and **6c** in a molar ratio 1:6.

3.4.1. (1*E*)-**5d**

^1H -NMR (C_6D_6 , 360 MHz): δ 7.35 and 7.05 (2:3H, Ph), 5.97 (1H, s, 4-H), 4.19 (2H, diastereotopic OCH_2CH_3), 2.90 (4H, m, 2OCH₂ morpholine), 2.80 (4H, m, NCH₂ morpholine), 1.70 (3H, s, NCCH₃) 1.30 [9H, s, $\text{C}(\text{CH}_3)_3$], 0.93 (3H, t, OCH_2CH_3). ^{13}C -NMR (CDCl_3 , 242 K): δ 252.2 (W-C), 203.2 and 199.4 [1: 4, *trans*- and *cis*-CO, $\text{W}(\text{CO}_5)$, 180.1 (C_q , $\text{C}=\text{N}^+$), 165.9 (C_q , COOCMe_3), 154.3 (C_q , C3), 139.4 and 134.6 (C_q each, C2 and *iC Ph*); 128.9, 128.5 and 127.5 (CH each, Ph), 123.1 (CH, C4), 79.9 (CMe_3), 73.7 (OCH_2CH_3), 66.2 (2OCH₂ morpholine), 51.7 (2NCH₂ morpholine), 27.4 (CMe_3), 26.2 (OCH_2CH_3), 15.2 (NCCH₃). IR (diffuse reflection), cm^{-1} : 2050.6 (20), 1900.2 (100) [$\nu(\text{C}\equiv\text{O})$, 1703.6 (20) [$\nu(\text{C=O})$.

3.4.2. (1*Z*)-**5d**

^1H -NMR (CDCl_3): δ 7.52 and 7.25 (2:3 H, m each, Ph), 6.19 (1H, s, 4-H), 4.22 (2H, diastereotopic OCH_2CH_3), 3.87 (4H, m, 2OCH₂ morpholine), 3.75 (4H, m, 2NCH₂ morpholine), 2.34 (3H, s, NCCH₃), 1.45 [9H, s, $\text{C}(\text{CH}_3)_3$], 1.14 (3H, OCH_2CH_3). ^{13}C -NMR (CDCl_3): δ [9] (W-C), 202.9 and 199.8 [1: 4, *trans*- and *cis*-CO, $\text{W}(\text{CO}_5)$, 178.0 (C_q , $\text{C}=\text{N}$), 165.9 (C_q ,

COOCMe_3), 153.1 (C_q , C3), 139.9 and 135.8 (C_q each, C2 and *iC Ph*); 128.1, 127.6 and 126.9 (CH each, Ph), 123.5 (CH, C4), 79.7 (CMe_3), 74.1 (OCH_2CH_3), 66.2 (2OCH₂, morpholine), 52.3 (2NCH₂, morpholine), 27.5 [$\text{C}(\text{CH}_3)_3$], 25.8 (NCCH₃), 15.3 (OCH_2CH_3). IR (diffuse reflection), cm^{-1} : 2058.6 (20), 1966.9 (90), 1935.6 (100) [$\nu(\text{C}\equiv\text{O})$, 1708.7 (20) [$\nu(\text{C=O})$.

3.4.3. Compound **6d**

^1H -NMR (CDCl_3): δ 7.25 (5H, s, Ph), 5.26 (1H, s, 4-H), 4.60–3.10 (10H, m, OCH₂ and NCH₂ morpholine each, and OCH_2CH_3), 1.78 [3H, s, $=\text{C}(\text{OEt})\text{CH}_3$], 1.07 [9H, s, $\text{C}(\text{CH}_3)_3$], 0.59 (3H, t, OCH_2CH_3). ^{13}C -NMR (CDCl_3): δ 254.2 (W-C), 202.5 and 199.1 [1:4, *trans*- and *cis*-CO, $\text{W}(\text{CO}_5)$, 165.6 (C_q , COOCMe_3); 145.5, 145.0 and 140.6 (C_q each; C1', C2 and C3), 131.2 (C_q , *iC Ph*); 128.1, 127.6 and 126.9 (CH each, Ph), 122.7 (CH, C4), 80.2 (CMe_3); 66.7, 66.3, 63.7 and 62.5 (2OCH₂ and 1NCH₂ morpholine each, and OCH_2CH_3), 52.8 (NCH₂ morpholine), 27.8 [$\text{C}(\text{CH}_3)_3$], 16.6 [$=\text{C}(\text{OEt})\text{CH}_3$], 14.1 (OCH_2CH_3). MS (70 eV), *m/e* (%), ^{184}W : 709 (10) [M^+], 569 (10) [$\text{M}^+ - 5\text{CO}$], 385 (20) [ligand], 57 (100). Anal. Found: C, 47.78; H, 4.21; N, 2.67. Calc. for $\text{C}_{28}\text{H}_{31}\text{NO}_9\text{W}$ (709.4): C, 47.41; H, 4.40; N, 1.97%.

3.5. Pentacarbonyl[1-ethoxy-5-(*t*-butoxy)-2-(1-morpholinium-1-ethylidene)-5-oxo-3,4-bis(phenyl)-penta-1,3-dien-1-yl]tungstate [(1*E*)-**5e**] and pentacarbonyl[2-(1-ethoxy-ethylidene)-5-(*t*-butoxy)-1-morpholinium-5-oxo-3,4-bis(phenyl)-3-penten-1-yl]tungstate (**6e**)

A mixture of pentacarbonyl(1-ethoxy-3-phenyl-2-propin-1-ylidene)tungsten (**1a**, 482 mg, 1.00 mmol) and 2-morpholino-1-phenyl-propene (**4d**, 170 mg, 1.00 mmol) in 20 ml of *n*-pentane is reacted as described above to give compound (1*E*)-**5e** (500 mg, 90%). (1*E*)-**5e** in CDCl_3 solution undergoes an isomerisation within 24 h at 20°C to give compound **6e** as the only product.

3.5.1. (1*E*)-**5e**

^1H -NMR (CDCl_3): δ 7.40–7.00 (10H, m, Ph), 6.80 (1H, s, 4-H), 4.28 (2H, q, OCH_2CH_3), 3.60 (4H, m, diastereotopic OCH₂ morpholine), 3.49 (4H, m, diastereotopic NCH₂ morpholine), 2.18 (3H, s, NCCH₃), 1.22 (3H, t, OCH_2CH_3).

3.5.2. Compound **6e**

^1H -NMR (CDCl_3): δ 7.30–6.80 (10H, m, Ph), 6.04 (1H, s, 4-H), 4.70–3.00 (10H, m, OCH₂ and NCH₂, morpholine each, and OCH_2CH_3), 1.76 (3H, s, CH₃), 0.54 (3H, t, OCH_2CH_3). ^{13}C -NMR (CDCl_3): δ 254.7 (W=C), 203.1 and 198.9 [1: 4, *trans*- and *cis*-CO, $\text{W}(\text{CO}_5)$; 142.5, 141.0 and 133.7 (C_q each; C1', C2 and C3), 137.1 and 135.1 (C_q each, *iC Ph*), 131–126 (CH

each, C₆H₅ and C4); 67.7, 64.1, 63.8, 62.6 and 53.2 (2OCH₂ and 2NCH₂, morpholine each, OCH₂CH₃), 16.9 [=C(OEt)CH₃], 14.6 (OCH₂CH₃). IR (diffuse reflection) cm⁻¹: 2058.6, 1979.7 and 1892.2 [ν (C≡O)]. MS (70 eV), *m/z* (%), ¹⁸⁴W: 685 (10) [M⁺], 545 (8) [M⁺ - 5CO], 361 (23) [ligand⁺], 332 (100).

4. Supplementary material

Crystallographic data (excluding structure factors) for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication CSD-147009 (**5a**), and CSD-147010 (**6a**). Copies of the data can be obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (Fax: +44-1223-336033; e-mail: deposit@ccdc.cam.ac.uk or www: http://www.ccdc.cam.ac.uk).

References

- [1] For a recent review on (1-alkynyl)carbene complexes see: R. Aumann, H. Nienaber, *Adv. Organomet. Chem.* 41 (1997) 163.
- [2] (a) R. Aumann, K. Roths, M. Grehl, *Synlett* (1993) 669. (b) R. Aumann, M. Kößmeier, K. Roths, R. Fröhlich, *Synlett* (1994) 1041. (c) A.G. Meyer, R. Aumann, *Synlett* (1995) 1011. (d) R. Aumann, A.G. Meyer, R. Fröhlich, *Organometallics* 15 (1996) 5018. (e) R. Aumann, M. Kößmeier, Ch. Mück-Lichtenfeld, F. Zippel, *Eur. J. Org. Chem.* (2000) 37.
- [3] For a recent review on reactions of metallahexatrienes see: R. Aumann, *Eur. J. Org. Chem.* (2000) 17.
- [4] (a) R. Aumann, K. Roths, M. Läge, B. Krebs, *Synlett* (1993) 667. (b) R. Aumann, K. Roths, R. Fröhlich, *Organometallics* 16 (1997) 5893.
- [5] R. Aumann, I. Göttker-Schnetmann, R. Fröhlich, O. Meyer, *Eur. J. Org. Chem.* (1999) 2545.
- [6] (a) A.G. Cook, *Enamines: Synthesis, Structure and Reactions*, in: A.G. Cook (Ed.), Marcel Dekker, New York, 1969, pp. 230–1107. (b) T. Nagasaka, H. Inoue, F. Hamaguchi *Heterocycles* 20 (1983) 1099. (c) T. Tokumitsu, *Bull. Chem. Soc. Jpn.* 59 (1986) 3871. (d) R.J.M. Egberink, W. Verboom, P.H. Benders, S. Harkema, D.N. Reinhoudt, *Recl. Trav. Chim. Pays-Bas* 107 (1988) 388. (e) W.K. Gibson, D. Leaver, *J. Chem. Soc. Sect. C* (1966) 324. (f) A. Halleux, H.G. Viehe, *J. Chem. Soc. Sect. C* (1968) 1726. (g) R. Fuks, H.G. Viehe, *Chemistry of the Acetylenes*, in: H.G. Viehe (Ed.), Marcel Dekker, New York, 1969, pp. 435–439.
- [7] (a) C.F. Huebener, L. Dorfman, M.M. Robinson, E. Donoghue, W.G. Pierson, P. Strachan, *J. Org. Chem.* 28 (1963) 3134. (b) G.A. Berchtold, G.F. Uhlig, *J. Org. Chem.* 28 (1963) 1459. (c) A.K. Bose, G. Mina, M.S. Manhas, E. Rzucidlo, *Tetrahedron Lett.* (1963) 1467. (d) A.J. Birch, E.G. Hutchinson, *J. Chem. Soc. Sect. C* (1971) 3671. (e) D.N. Reinhoudt, C.G. Kouwenhoven, *Tetrahedron Lett.* (1973) 3751. (f) G.J. Vos, P.H. Benders, D.N. Reinhoudt, R.J.M. Egberink, S. Harkema, G.J. van Hummel, *J. Org. Chem.* 51 (1986) 2004.
- [8] For related reactions of enol ethers with compounds **1** see: (a) K.L. Faron, W.D. Wulff, *J. Am. Chem. Soc.* 110 (1988) 8727. (b) F. Camps, J.M. Moretó, S. Ricart, J.M. Viñas, E. Molins, C. Miravittles, *J. Chem. Soc. Chem. Commun.* (1989) 1560. (c) L. Jordi, J.M. Moretó, S. Ricart, J.M. Viñas, E. Molins, C. Miravittles, *J. Organomet. Chem.* 444 (1993) C28. (d) L. Jordi, F. Camps, S. Ricart, J.M. Viñas, J.M. Moretó, M. Mejias, E. Molins, *J. Organomet. Chem.* 494 (1995) 53. (e) For a recent review on this topic see: W.D. Wulff, K.L. Faron, J. Su, J.P. Springer, A.L. Rheingold, *J. Chem. Soc., Perkin Trans. I* (1999) 197.
- [9] Signal not observed due to dynamic line broadening.
- [10] Data sets were collected with Enraf Nonius CAD4 diffractometers. Programs used: data collection EXPRESS (Nonius B.V. 1994), data reduction MOLEN (K. Fair, Enraf-Nonius B.V. 1990), structure solution SHELXS-93 (G.M. Sheldrick, *Acta Crystallogr. Sect. A* 46 (1990) 467), structure refinement SHELXL-93 (G.M. Sheldrick, Universität Göttingen, Germany, 1997), graphics SCHAKAL (E. Keller, Universität Freiburg, 1997).
- [11] R. Aumann, I. Göttker-Schnetmann, R. Fröhlich, P. Saarenketo, Ch. Holst, *Chem. Eur. J.* (accepted for publication).